title: [Nephropathy and metabolic heart diseases. Cardiac risk in kidney malfunction].
mesh_terms: D002318:Cardiovascular Diseases / Q000209:etiology* / Q000401:mortality / Q000628:therapy; D002423:Cause of Death; D003924:Diabetes Mellitus, Type 2 / Q000209:etiology* / Q000401:mortality / Q000628:therapy; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications* / Q000401:mortality / Q000628:therapy; D024821:Metabolic Syndrome / Q000209:etiology* / Q000401:mortality / Q000628:therapy; D011719:Pyrazines / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D006435:Renal Dialysis / Q000401:mortality; D012307:Risk Factors; D000068900:Sitagliptin Phosphate; D015996:Survival Rate; D014230:Triazoles / Q000627:therapeutic use
chemical_list: D054873:Dipeptidyl-Peptidase IV Inhibitors; D011719:Pyrazines; D014230:Triazoles; D000068900:Sitagliptin Phosphate